Sign In
Buy ZEAL
$17.59
+0 (+0%)
At Close: Jan 27, 2023
Steven R. Smith, MD, joins Zealand Pharma as Senior Global Medical Advisor in Obesity
11:00am, Tuesday, 07'th Jan 2025
Press Release – No. 2 / 2025 Steven R.
Zealand Pharma to present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13th
11:00am, Monday, 06'th Jan 2025
Press Release – No. 1 / 2025 Zealand Pharma to present at the 43rd Annual J.P.
Company announcement – No. 53 / 2024 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenh
Zealand Pharma major shareholder announcement: The Capital Group Companies, Inc.
11:30am, Wednesday, 25'th Dec 2024
Company announcement – No. 52 / 2024 Zealand Pharma major shareholder announcement: The Capital Group Companies, Inc. Copenhagen, Denmark, 25 December 2024 – Zealand Pharma A/S (“Zealand”)
Company announcement – No. 51 / 2024 U.S. Food and Drug Administration issues Complete Response Letter for the glepaglutide New Drug Application for the treatment of short bowel syndrome The FDA con
Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity
09:00am, Tuesday, 10'th Dec 2024
Press Release – No. 12 / 2024 Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity Zealand Pharma announces that the f
Zealand Pharma to participate in the Jefferies London Healthcare Conference
12:00pm, Wednesday, 13'th Nov 2024
Press Release – No. 11 / 2024 Zealand Pharma to participate in the Jefferies London Healthcare Conference Copenhagen, Denmark, November 13, 2024 – Zealand Pharma A/S (CVR-no.
Company announcement – No. 50 / 2024 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenh
Zealand Pharma provides U.S. regulatory update on dasiglucagon in congenital hyperinsulinism
06:45pm, Tuesday, 08'th Oct 2024
Company announcement – No. 48 / 2024 Zealand Pharma provides U.S. regulatory update on dasiglucagon in congenital hyperinsulinism U.S. Food and Drug Administration (FDA) issues Complete Response Let
Company announcement – No. 47 / 2024 Zealand Pharma announces that Boehringer receives U.S. FDA Breakthrough Therapy designation and initiates two Phase III trials in MASH for survodutide The U.S. F
Zealand Pharma to participate in the 2024 Cantor Global Healthcare Conference on September 18th
11:01am, Friday, 13'th Sep 2024
Press Release – No. 9 / 2024 Zealand Pharma to participate in the 2024 Cantor Global Healthcare Conference on September 18th Copenhagen, Denmark, September 13, 2024 – Zealand Pharma A/S (CVR-no
Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants
11:01am, Thursday, 12'th Sep 2024
Company announcement – No. 45 / 2024 Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants Copenhagen, Denmark, September 12, 2024 – Zealand Pharma A/S (“Z
Company announcement – No. 44 / 2024 Zealand Pharma announces positive topline results from 13-week Phase 1b multiple ascending dose clinical trial with GLP-1/GLP-2 receptor dual agonist dapiglutide
Company announcement – No. 43 / 2024 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenh
Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants
04:00pm, Thursday, 22'nd Aug 2024
Company announcement – No. 41 / 2024 Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants Copenhagen, Denmark, August 22, 2024 – Zealand Pharma A/S (“Zeal
